US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says

MT NewswiresDec 22, 2024 22:19 ET

Cynata Therapeutics Started With A$0.75/Share Target Price by Euroz Hartleys>CYP.AU

Dow JonesNov 5, 2024 22:00 ET

Cynata Therapeutics Started at Spec Buy by Euroz Hartleys >CYP.AU

Dow JonesNov 5, 2024 22:00 ET

Cynata Therapeutics Ltd: Annual Report to Shareholders

ASXOct 17, 2024 22:44 ET · Announcements

Cynata Therapeutics Ltd: Appendix 4E & Annual Report

Aug 29, 2024 04:07 ET · Announcements

Stocks of the Hour: NOVONIX, Cynata Therapeutics, Cauldron Energy

sharecafeAug 7, 2024 21:51 ET